Copyright
©The Author(s) 2018.
World J Gastroenterol. Apr 14, 2018; 24(14): 1550-1561
Published online Apr 14, 2018. doi: 10.3748/wjg.v24.i14.1550
Published online Apr 14, 2018. doi: 10.3748/wjg.v24.i14.1550
LPZ 15 mg | VPZ 10 mg | VPZ 20 mg | |||||
Estimate (%)1 | Estimate (%)1 | Difference2 and 95%CI (%) | Fisher exact test, P value3 | Estimate (%)1 | Difference2 and 95%CI (%) | Fisher exact test, P value3 | |
Age (yr) | |||||||
< 65 | 14.4 (19/132) | 4.3 (6/139) | -10.1 [-16.95, -3.20] | 0.0056 | 0.0 (0/136) | -14.4 [-20.38, -8.41] | < 0.0001 |
≥ 65 to < 75 | 21.7 (10/46) | 7.0 (3/43) | -14.8 [-28.91, -0.62] | 0.0711 | 7.0 (3/43) | -14.8 [-28.91, -0.62] | 0.0711 |
≥ 75 | 22.2 (4/18) | 6.7 (1/15) | -15.6 [-38.54, 7.43] | 0.3457 | 4.5 (1/22) | -17.7 [-38.76, 3.41] | 0.1554 |
Sex | |||||||
Male | 13.9 (19/137) | 6.3 (10/159) | -7.6 [-14.49, -0.67] | 0.0321 | 1.3 (2/159) | -12.6 [-18.65, -6.57] | < 0.0001 |
Female | 23.7 (14/59) | 0.0 (0/38) | -23.7 [-34.58, -12.87] | 0.0007 | 4.8 (2/42) | -19.0 [-31.59, -6.35] | 0.0120 |
Smoking classification | |||||||
Never smoked | 22.4 (17/76) | 1.9 (1/54) | -20.5 [-30.55, -10.48] | 0.0006 | 5.0 (3/60) | -17.4 [-28.24, -6.50] | 0.0062 |
Current smoker | 20.0 (8/40) | 6.6 (4/61) | -13.4 [-27.31, 0.42] | 0.0588 | 0.0 (0/57) | -20.0 [-32.40, -7.60] | 0.0005 |
Ex-smoker | 10.0 (8/80) | 6.1 (5/82) | -3.9 [-12.27, 4.47] | 0.3998 | 1.2 (1/84) | -8.8 [-15.78, -1.84] | 0.0160 |
Erosive esophagitis grade4 | |||||||
LA Grade A/B | 11.0 (17/155) | 3.1 (5/159) | -7.8 [-13.44, -2.21] | 0.0075 | 1.3 (2/158) | -9.7 [-14.92, -4.48] | 0.0002 |
LA Grade C/D | 39.0 (16/41) | 13.2 (5/38) | -25.9 [-44.26, -7.47] | 0.0114 | 4.7 (2/43) | -34.4 [-50.58, -18.17] | 0.0001 |
CYP2C19 genotype | |||||||
Extensive metabolizers | 19.6 (31/158) | 5.4 (9/166) | -14.2 [-21.28, -7.11] | 0.0001 | 1.8 (3/168) | -17.8 [-24.34, -11.33] | < 0.0001 |
Poor metabolizers | 5.3 (2/38) | 3.2 (1/31) | -2.0 [-11.48, 7.40] | 1.0000 | 3.0 (1/33) | -2.2 [-11.43, 6.97] | 1.0000 |
H. pylori infection status | |||||||
Positive | 3.7 (1/27) | 2.7 (1/37) | -1.0 [-9.84, 7.83] | 1.0000 | 0.0 (0/27) | -3.7 [-10.83, 3.42] | 1.0000 |
Negative | 18.9 (32/169) | 5.6 (9/160) | -13.3 [-20.21, -6.41] | 0.0003 | 2.2 (4/179) | -16.7 [-22.99. -10.41] | < 0.0001 |
- Citation: Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24(14): 1550-1561
- URL: https://www.wjgnet.com/1007-9327/full/v24/i14/1550.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i14.1550